Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 399,889 shares at $0.61 ($251K) on 2025-12-29, disclosed to the SEC on 2025-12-29.
Scheduled sale ($251k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.69 | 59,307 | $41K | 16.3% |
| 2 | $0.63 | 71,428 | $45K | 17.9% |
| 3 | $0.65 | 16,310 | $11K | 4.2% |
| 4 | $0.63 | 35,632 | $22K | 8.9% |
| 5 | $0.61 | 108,606 | $66K | 26.3% |
| 6 | $0.61 | 108,606 |
| $66K |
| 26.3% |
| Total | $0.63 avg | 399,889 | $251K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |